Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Respiratory Aspiration 1Lymphoma, Follicular 1COVID-19 1

Interventions

Standard of Care 2COVID-19 Vaccines 2regorafenib 1proxalutamide 1palbociclib 1cilgavimab and tixagevimab drug combination 1bemcentinib 1acalabrutinib 1Sorafenib 1Sodium Chloride 1Rabeprazole 1NVX-CoV2373 adjuvated lipid nanoparticle 1Janus Kinase Inhibitors 1Interleukin-7 1IBIO123 1Gelsolin 1COH04S1 COVID-19 vaccine 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 12019-nCoV Vaccine mRNA-1273 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 11-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × COVID-19 × IBIO123 × Clear all
NCT05303376 2023-09-13

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

Immune Biosolutions Inc

Phase 1/2 Completed
123 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡